<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04772079</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-126</org_study_id>
    <secondary_id>2019-004879-39</secondary_id>
    <nct_id>NCT04772079</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Drug Levels, Efficacy and Safety of BMS-986165 in Adolescent Participants With Moderate to Severe Plaque Psoriasis</brief_title>
  <official_title>A Multicenter, Randomized, Double-Blind Placebo-Controlled Phase 3 Study to Evaluate the Pharmacokinetics, Efficacy and Safety of BMS-986165 in Adolescent Subjects With Moderate to Severe Plaque Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this pediatric study is to evaluate the drug levels, efficacy and safety of&#xD;
      BMS-986165 in adolescent participants aged 12 to &lt;18 years with moderate to severe plaque&#xD;
      psoriasis. This study has two parts. Part A will evaluate the drug levels of BMS-986165 in&#xD;
      adolescent participants ages 12 to &lt;18 years to enable selection of 2 dose levels to be&#xD;
      studied in Part B. Part B will assess the efficacy and safety of two dose levels in&#xD;
      adolescents participants with moderate to severe plaque psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 23, 2021</start_date>
  <completion_date type="Anticipated">April 16, 2024</completion_date>
  <primary_completion_date type="Anticipated">April 15, 2024</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Steady-state maximum observed concentration (Cmax) for BMS-986165 at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Steady-state trough observed plasma concentration (Ctrough) for BMS-986165 at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Average concentration steady state (Css-avg) for BMS-986165 at Week 2</measure>
    <time_frame>Week 2</time_frame>
    <description>Part A</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with at least 75% improvement in Psoriasis Area and Severity Index (PASI 75) at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of subjects with an static Physician's Global Assessment (sPGA) score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse Events (AEs)</measure>
    <time_frame>Up to 424 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of serious adverse events (SAEs)</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Chemistry panel tests</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hemoglobin A1C tests</measure>
    <time_frame>Up to 410 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Infectious serologies tests</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Tuberculosis (TB) tests</measure>
    <time_frame>Up to 42 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Lipid panel tests</measure>
    <time_frame>Up to 368 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Serum immunoglobulin level tests</measure>
    <time_frame>Up to 368 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Fasting plasma glucose tests</measure>
    <time_frame>Up to 368 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Pregnancy test for women of childbearing potential only</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in lymphocyte subsets and function</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in cytokine levels</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in physical examination findings</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Body temperature</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Systolic and diastolic blood pressure</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of growth: Body weight</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of growth: Height</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of growth: Body mass index (BMI)</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Monitoring of growth: Tanner staging (sexual maturation)</measure>
    <time_frame>Up to 466 days</time_frame>
    <description>Part A and Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least 75% improvement in PASI (PASI 75) at Week 16 for the comparison of the half-standard dose of BMS-986165 vs placebo</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with an sPGA score of 0 (clear) or 1 (almost clear) with at least a 2-point reduction from baseline at Week 16 for the comparison of the half-standard dose of BMS-986165 vs placebo</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with at least 90% improvement in PASI (PASI 90) at Week 16 for the comparison of BMS-986165 vs placebo</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in PASI at Week 16 for comparison of BMS-986165 vs placebo</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in BSA involvement at Week 16 for comparison of BMS-986165 vs placebo</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in CDLQI score at Week 16 for comparison of BMS-986165 vs placebo</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in subject reported visual analog scale (VAS) for subject's assessment of joint pain at Week 16 (only for subjects with confirmed JPsA prior to baseline) for comparison of BMS-986165 vs placebo</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in VAS for subject's Global Assessment of Joint Disease; at Week 16 (only for subjects with confirmed JPsA prior to baseline) for comparison of BMS-986165 vs placebo</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects achieving American College of Rheumatology Pediatric 30 (ACR Pedi 30) response at Week 16 for subjects with confirmed JPsA prior to baseline</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B&#xD;
ACR Pedi 30 response is defined as subjects with at least 30% improvement from baseline in 3 of any 6 variables in the core set, while no more than one of the remaining variables can worsen by &gt; 30% for comparison of BMS-986165 vs placebo</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects using topical corticosteroid at Week 16 for comparison of BMS-986165 vs placebo</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of subjects with protective titers of antibodies to measles, tetanus and pertussis at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state maximum observed concentration (Cmax) for BMS-986165 at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Steady-state trough observed plasma concentration (Ctrough) for BMS-986165 at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Average concentration steady state (Css-avg) for BMS-986165 at Week 16</measure>
    <time_frame>Week 16</time_frame>
    <description>Part B</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Plaque Psoriasis</condition>
  <arm_group>
    <arm_group_label>Active treatment (BMS-986165) standard dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Active treatment (BMS-986165) half-standard dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Active treatment (BMS-986165) half-standard dose</arm_group_label>
    <arm_group_label>Active treatment (BMS-986165) standard dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo matching BMS-986165</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Males and females aged 12 to &lt;18 years&#xD;
&#xD;
          -  Plaque psoriasis for at least 6 months&#xD;
&#xD;
          -  Moderate to severe disease&#xD;
&#xD;
          -  Candidate for phototherapy or systemic therapy&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Weighing ≤ 30.0 kg at screening&#xD;
&#xD;
          -  Other forms of psoriasis&#xD;
&#xD;
          -  History of recent infection&#xD;
&#xD;
          -  Prior exposure to BMS-986165 or active comparator&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Recruiting sites have contact information. Please contact the sites directly. If there is no contact information,</last_name>
    <phone>please email:</phone>
    <email>Clinical.Trials@bms.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>First line of the email MUST contain NCT # and Site #.</last_name>
  </overall_contact_backup>
  <location>
    <facility>
      <name>The Skin Hospital</name>
      <address>
        <city>Sydney</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johanna Kuchel, Site 0020</last_name>
      <phone>+61286512027</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0002</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Veracity Clinical Research</name>
      <address>
        <city>Brisbane</city>
        <state>Queensland</state>
        <zip>4102</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lynda Spelman, Site 0003</last_name>
      <phone>+61730391300</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sinclair Dermatology</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samantha Eisman, Site 0001</last_name>
      <phone>+61390130099</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2J 7E1</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0010</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Markham</city>
        <state>Nunavut</state>
        <zip>L3P 1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0008</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H3T 1C5</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0009</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Nice</city>
        <zip>06202</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0012</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Paris</city>
        <zip>75019</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0021</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Krakow</city>
        <zip>30-510</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0011</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Lodz</city>
        <zip>90-436</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0006</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Warszawa</city>
        <zip>02-507</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Site 0004</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Wroclaw</city>
        <zip>51-620</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0005</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Alicante</city>
        <zip>03010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0017</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Barakaldo</city>
        <zip>48903</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0026</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Esplugues de Llobregat</city>
        <zip>08950</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0014</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Las Palmas De GC</city>
        <zip>35019</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0016</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0027</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0022</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Connor Downs</city>
        <zip>TR27 5DT</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Site 0019</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Canada</country>
    <country>France</country>
    <country>Poland</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>February 24, 2021</study_first_submitted>
  <study_first_submitted_qc>February 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2021</study_first_posted>
  <last_update_submitted>September 28, 2021</last_update_submitted>
  <last_update_submitted_qc>September 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Adolescent Psoriasis</keyword>
  <keyword>BMS-986165</keyword>
  <keyword>Clinical trial</keyword>
  <keyword>Deucravacitinib</keyword>
  <keyword>Pediatric</keyword>
  <keyword>Pediatric Psoriasis</keyword>
  <keyword>Plaque Psoriasis</keyword>
  <keyword>Psoriasis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BMS-986165</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

